Clinical
Phase 2 Trial
Mid-stage efficacy and dose-ranging study, typically 100–300 patients with the target condition.
Definition
Phase 2 establishes whether a drug has a meaningful clinical effect and selects doses for Phase 3. Common duration 3–12 months. Failure rate at Phase 2 is high.
Related terms
Back to the full peptide glossary.